These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34088773)

  • 61. Nomograms to predict outcomes after
    Gafita A; Calais J; Grogan TR; Hadaschik B; Wang H; Weber M; Sandhu S; Kratochwil C; Esfandiari R; Tauber R; Zeldin A; Rathke H; Armstrong WR; Robertson A; Thin P; D'Alessandria C; Rettig MB; Delpassand ES; Haberkorn U; Elashoff D; Herrmann K; Czernin J; Hofman MS; Fendler WP; Eiber M
    Lancet Oncol; 2021 Aug; 22(8):1115-1125. PubMed ID: 34246328
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
    Goetz TI; Lang EW; Prante O; Maier A; Cordes M; Kuwert T; Ritt P; Schmidkonz C
    Ann Nucl Med; 2020 Apr; 34(4):244-253. PubMed ID: 32114682
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT.
    Gosewisch A; Ilhan H; Tattenberg S; Mairani A; Parodi K; Brosch J; Kaiser L; Gildehaus FJ; Todica A; Ziegler S; Bartenstein P; Böning G
    EJNMMI Res; 2019 Aug; 9(1):76. PubMed ID: 31414241
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of calculation method on kidney dosimetry in
    Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
    Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 66. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Determination of Critical Organ Doses with
    Yilidir G; Demir M
    J Med Phys; 2024; 49(2):304-310. PubMed ID: 39131436
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dosimetry and safety of
    Paganelli G; Sarnelli A; Severi S; Sansovini M; Belli ML; Monti M; Foca F; Celli M; Nicolini S; Tardelli E; Marini I; Matteucci F; Giganti M; Di Iorio V; De Giorgi U
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3008-3017. PubMed ID: 32430583
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in
    Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
    Med Phys; 2019 Dec; 46(12):5861-5866. PubMed ID: 31587333
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A step toward simplified dosimetry of radiopharmaceutical therapy via SPECT frame duration reduction.
    Yazdani E; Asadi M; Geramifar P; Karamzade-Ziarati N; Vosoughi H; Kazemi-Jahromi M; Sadeghi M
    Appl Radiat Isot; 2024 Aug; 210():111378. PubMed ID: 38820867
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy.
    Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4077-4088. PubMed ID: 34041564
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.
    Kesavan M; Meyrick D; Gallyamov M; Turner JH; Yeo S; Cardaci G; Lenzo NP
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33799431
    [TBL] [Abstract][Full Text] [Related]  

  • 74. First-Strike Rapid Predictive Dosimetry and Dose Response for
    Kao YH; Falzone N; Pearson M; Sivaratnam D
    J Nucl Med Technol; 2024 Sep; 52(3):212-218. PubMed ID: 38901967
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.
    Meyer C; Prasad V; Stuparu A; Kletting P; Glatting G; Miksch J; Solbach C; Lueckerath K; Nyiranshuti L; Zhu S; Czernin J; Beer AJ; Slavik R; Calais J; Dahlbom M
    EJNMMI Res; 2022 Oct; 12(1):65. PubMed ID: 36182983
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
    Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
    Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Response Assessment and Prediction of Progression-Free Survival by
    Khreish F; Wiessner M; Rosar F; Ghazal Z; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439768
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Radiation Dosimetry in
    Jackson P; Hofman M; McIntosh L; Buteau JP; Ravi Kumar A
    Semin Nucl Med; 2022 Mar; 52(2):243-254. PubMed ID: 34893320
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase I/II Trial of the Combination of
    Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L
    Eur Urol Oncol; 2021 Dec; 4(6):963-970. PubMed ID: 32758400
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T.
    Brosch-Lenz J; Uribe C; Gosewisch A; Kaiser L; Todica A; Ilhan H; Gildehaus FJ; Bartenstein P; Rahmim A; Celler A; Ziegler S; Böning G
    EJNMMI Phys; 2021 Mar; 8(1):26. PubMed ID: 33709253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.